Back to discover
Drug

Equol

Approved medicine
ClassEstrogen receptor beta agonistResearchOngoing clinical research

Also known as S-equol, EQUOL, (-)-.

RxNorm1803717ChEMBLCHEMBL198877UNII2T6D2HPX7Q
2
Research papers
3
Active clinical trials
Estrogen receptor beta
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Arterial Stiffness, Cognition and Equol

Clinical trial2026-10-31Primary completion · ClinicalTrials.gov

Equol Supplementation for Improving Vascular Function in Postmenopausal Women With CKD

Clinical trial2026-06-02Results expected Q4 2030 · ClinicalTrials.gov

Acute Equol Supplementation and Vascular Function in Postmenopausal Women With and Without CKD

Clinical trial2025-09-30Results expected Q4 2026 · ClinicalTrials.gov

From Gut to Hormones: Unraveling the Role of Gut Microbiota in (Phyto)Estrogen Modulation in Health and Disease.

Research2024-02-11Molecular nutrition & food research

A Pre-surgical Clinical Trial of Therapy With S-equol in Women With Triple Negative Breast Cancer.

Clinical trial2020-06-30Completed · ClinicalTrials.gov

Equol: A Bacterial Metabolite from The Daidzein Isoflavone and Its Presumed Beneficial Health Effects.

Research2019-09-16Nutrients

Randomized, Double Blind, Multicenter, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4 Weeks Treatment With AUS 131 (S Equol) on Benign Prostatic Hyperplasia

Clinical trial2017-05-19Results posted · ClinicalTrials.gov

Randomized, Double Blind, Multicenter, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4 Weeks Treatment With AUS-131 (S-equol) on Vasomotor Symptoms in Menopausal Patients

Clinical trial2014-04-08Results posted · ClinicalTrials.gov

Randomized, Double-Blind, Rising Multiple Dose Study of S-Equol in Normal Volunteers

Clinical trial2009-04-01Completed · ClinicalTrials.gov

Randomized, Double-Blind, Single Rising Dose Study of S-equol in Normal Volunteers

Clinical trial2008-12-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Equol
Aliases & brands
S-equolEQUOL, (-)-
RxNorm CUI
1803717
ChEMBL ID
CHEMBL198877
UNII
2T6D2HPX7Q
Primary mechanism
Estrogen receptor beta agonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Estrogen receptor beta
ESR2 · Q92731
AGONISTEstrogen receptor beta agonist

Clinical trials

8 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
8
registered trials across all phases
LATEST COMPLETION 2020
3
Active studies
2
Recruiting
5
Completed
PHASE DISTRIBUTIONn = 8
Early Phase 11Phase 12Phase 25

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Pre-surgical Clinical Trial of Therapy With S-equol in Women With Triple Negative Breast Cancer.

CompletedPH IThe University of Texas Health Science Center at San Antonion=392020

Randomized, Double Blind, Multicenter, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4 Weeks Treatment With AUS 131 (S Equol) on Benign Prostatic Hyperplasia

CompletedPH IIAusio Pharmaceuticals, LLCn=1162016

Randomized, Double Blind, Multicenter, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4 Weeks Treatment With AUS-131 (S-equol) on Vasomotor Symptoms in Menopausal Patients

CompletedPH IIAusio Pharmaceuticals, LLCn=1692011

Randomized, Double-Blind, Rising Multiple Dose Study of S-Equol in Normal Volunteers

CompletedPH IAusio Pharmaceuticals, LLCn=412009

Randomized, Double-Blind, Single Rising Dose Study of S-equol in Normal Volunteers

CompletedPH IAusio Pharmaceuticals, LLCn=602008

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
2019–2024
Major research themes3
Gastrointestinal Microbiome2Breast Neoplasms1Diet1
Journals, researchers & institutions
Top journals
  • Molecular nutrition & food research1
  • Nutrients1
Leading researchers
  • Dua A1
  • Duyar-Ayerdi S1
  • Flórez AB1
  • Kumar R1
  • Kumari N1
  • Kumari R1
  • Mayo B1
  • Ojesina AI1
Leading institutions
free-text, unnormalised
  • College of Commerce1
  • Instituto de Investigación Sanitaria del Principado de Asturias (ISPA)1
  • Instituto de Productos Lácteos de Asturias (IPLA)1
  • Magadh University1
  • Medical College of Wisconsin1
  • Shivaji College1

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Estrogens

Studied across the same disease area as Equol in the shared literature.

1 shared disease1 shared paper
Daidzein

Frequently co-studied with Equol in the research literature.

1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials